Phenotypes associated with this allele

• Allele Symbol: Tg(tetO/CMV-KRAS*G12C)9.1Msmi
• Allele Name: transgene insertion 9.1, Mark Miller
• Allele ID: MGI:3693226
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cx1	Tg(SFTPC-rtTA)5Jaw/0 Tg(tetO/CMV-KRAS*G12C)9.1Msmi/0	involves: FVB/N	MGI:3693291
cx2	Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO/CMV-KRAS*G12C)9.1Msmi/0	involves: FVB/N	MGI:3693292

Genotype
MGI:3693291

cx1

• Allelic Composition: Tg(SFTPC-rtTA)5Jaw/0; Tg(tetO/CMV-KRAS*G12C)9.1Msmi/0
• Genetic Background: involves: FVB/N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

respiratory system

abnormal lung morphology ( J:102839 )

• after 12 days of doxycycline (DOX) treatement, small, hyperplastic lung foci are detected; untreated mice have normal lungs

increased lung adenoma incidence ( J:102839 )

abnormal pulmonary alveolus epithelium morphology ( J:102839 )

• after 5 weeks of DOX treatment, extensive epithelial hyperplasia of alveolar region of lung is observed; untreated mice have normal lungs

abnormal respiratory system physiology ( J:102839 )

abnormal surfactant physiology ( J:102839 )

• alveolar lipoproteinosis is regularly found, indicating abnormal surfactant metabolism

neoplasm

increased tumor incidence ( J:102839 )

• after 3 months treatment, visible macroscopic lesions are found; tumor incidence at 3 months is 55%, with multiplicity of 1.7 tumors/mouse

• lesions are <1mm in size

• early hyperplastic lesions are of alveologenic origin

• at 6 and 9 months DOX treatment, visible lesions increase in number; multiplicity is 10.2 and 12.5 tumors/mouse after 9 and 12 months, lower than Scgb1a1/KRAS bitransgenic mice; treated monotransgenic mice show no incidence

• when DOX treatment was stopped after 9 months, within 2 weeks only 4 tumors are visible on lung surface and by 1 month, no tumors are visible, and with minimal hyperplastic foci microscopically detectable, showing no proliferation (or apoptosis)

increased lung adenoma incidence ( J:102839 )

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
lung benign neoplasm		DOID:3683		J:102839

Genotype
MGI:3693292

cx2

• Allelic Composition: Tg(Scgb1a1-rtTA)1Jaw/0; Tg(tetO/CMV-KRAS*G12C)9.1Msmi/0
• Genetic Background: involves: FVB/N

respiratory system

abnormal lung morphology ( J:102839 )

• after 12 days of doxycycline (DOX) treatement, small, hyperplastic lung foci are detected; untreated mice have normal lungs

increased lung adenoma incidence ( J:102839 )

• single adenoma was detected at 3 months; at 6, 9, and 12 months of treatment, incidence increases; mice develop higher incidence of proliferative changes with lower latency than SFTPC/KRAS mice

increased lung adenocarcinoma incidence ( J:102839 )

• at 12 months of treatment, 2 adenomas have progressed to low grade carcinomas

abnormal pulmonary alveolus epithelium morphology ( J:102839 )

• after 5 weeks of DOX treatment, extensive epithelial hyperplasia of alveolar region of lung is observed; untreated mice have normal lungs

neoplasm

increased tumor incidence ( J:102839 )

• after 3 months treatment, visible macroscopic lesions are found; tumor incidence at 3 months is 55%, with multiplicity of 3.5 tumors/mouse

• lesions are <1mm in size

• early hyperplastic lesions are of bronchiolar origin

• at 6 and 9 months DOX treatment, visible lesions increase in number; multiplicity is 28.8 and 34 tumors/mouse after 9 and 12 months, higher than SFTPC/KRAS bitransgenic mice; treated monotransgenic mice show no tumor incidence

• when DOX treatment was stopped after 9 months, within 2 weeks only 4 tumors are visible on lung surface; these remain after 1 months; minimal hyperplastic foci microscopically are detectable, showing no proliferation (or apoptosis)

increased lung adenoma incidence ( J:102839 )

• single adenoma was detected at 3 months; at 6, 9, and 12 months of treatment, incidence increases; mice develop higher incidence of proliferative changes with lower latency than SFTPC/KRAS mice

increased lung adenocarcinoma incidence ( J:102839 )

• at 12 months of treatment, 2 adenomas have progressed to low grade carcinomas

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
lung benign neoplasm		DOID:3683		J:102839